OVERALL Abstract The Michigan Alzheimer?s Disease Core Center (Michigan ADCC) aims to foster and enhance innovative research in Alzheimer?s disease (AD) and related dementias with a long term goal of developing targeted therapies for these challenging disorders. This center will build on the existing deep infrastructure and research strengths in dementia and aging research at the University of Michigan (UM). The Michigan ADCC will emphasize research that seeks to identify, understand, and modulate the non--amyloid factors that contribute to brain dysfunction and neurodegeneration in AD and other dementias. The rationale for this focus is that while recent advances have defined a central role for -amyloid in AD, many potentially modifiable factors beyond -amyloid contribute to brain dysfunction and degeneration yet remain poorly understood. The Michigan ADCC will leverage established strengths in brain imaging, dementia risk identification and disclosure, mechanistic studies of neurodegenerative proteinopathies, and predictive Big Data analytics to achieve this objective. A truly regional center, the Michigan ADCC will promote research across the UM campus, throughout the state of Michigan via collaborations with our partner universities Michigan State University and Wayne State University, and across the nation through collaborations with other NIA-sponsored AD Centers (ADCs) and programs. The Michigan ADCC has four goals: 1) Foster, catalyze and perform research of the highest potential impact in AD and related neurodegenerative disorders; 2) Promote regional efforts to understand, diagnose and treat AD and related dementias through collaborative scientific and outreach efforts; 3) Provide a wide range of training and research opportunities in the dementias for health care professionals, scientists, and students through innovative educational and mentoring efforts; and 4) Collaborate with other ADCs, the NACC, and other multi-center research efforts to move the field closer to effective therapies for this group of devastating diseases. Success in achieving these goals will be ensured through the fully integrated activities of six cores (Administrative; Clinical; Data Management and Statistical; Neuropathology; Outreach and Recruitment; and Research Education Component ), and through close collaboration with related programs including the UM Protein Folding Diseases Initiative, Claude D. Pepper Older Americans Independence Center, Udall Center of Excellence for Parkinson?s Disease Research, and Healthier Black Elders Center of the Michigan Center for Urban African American Aging Research. These and other collaborations have led to newly developed emphases on the detection of early cognitive decline in an underserved population (African Americans in Detroit) and on novel potential biomarkers of disease. The Center?s extensive preliminary organization and teams of experts ensure that, upon receiving NIA designation, the Michigan ADCC will have an immediate impact, both regionally and nationally, in enhancing research to better understand and treat AD and related forms of dementia.

Public Health Relevance

Alzheimer's Disease (AD) and related dementias represent one of the fastest growing health problems in the United States and in the state of Michigan. Building on longstanding strengths in dementia research at the University of Michigan (UM) and facilitated by partnership with the state of Michigan?s two other major research universities, Michigan State University and Wayne State University, the Michigan ADCC will lead a regional effort to identify, understand and modulate the many non- amyloid factors that contribute to brain dysfunction and degeneration in AD and related dementias.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG053760-05
Application #
9980230
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Elliott, Cerise
Project Start
2016-08-15
Project End
2021-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Neurology
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Kalinin, Alexandr A; Allyn-Feuer, Ari; Ade, Alex et al. (2018) 3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification. Sci Rep 8:13658
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
González, Hector M; Tarraf, Wassim; Vásquez, Priscilla et al. (2018) Metabolic Syndrome and Neurocognition Among Diverse Middle-Aged and Older Hispanics/Latinos: HCHS/SOL Results. Diabetes Care 41:1501-1509
Rahman-Filipiak, Annalise M; Giordani, Bruno; Heidebrink, Judith et al. (2018) Self- and Informant-Reported Memory Complaints: Frequency and Severity in Cognitively Intact Individuals and those with Mild Cognitive Impairment and Neurodegenerative Dementias. J Alzheimers Dis 65:1011-1027
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Ornstein, Katherine A; Garrido, Melissa M; Siu, Albert L et al. (2018) Impact of In-Hospital Death on Spending for Bereaved Spouses. Health Serv Res 53 Suppl 1:2696-2717
Christensen, Kurt D; Uhlmann, Wendy R; Roberts, J Scott et al. (2018) A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genet Med 20:132-141
Tiernan, Chelsea T; Ginsberg, Stephen D; He, Bin et al. (2018) Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease. Neurobiol Dis 117:125-136

Showing the most recent 10 out of 106 publications